一种靶向甲状腺刺激激素受体的溶酶体靶向嵌合体及其应用
By constructing a lysosomal targeting chimera that targets the thyroid-stimulating hormone receptor (TSHR-Lytac), and utilizing the TSHR nanobody with the IGF-2R binding peptide linker arm, selective lysosomal degradation of TSHR is achieved, overcoming the limitations of existing technologies in the treatment of hyperthyroidism and GO, and providing a more effective treatment method.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV
- Filing Date
- 2026-03-18
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies have limitations in treating hyperthyroidism and thyroid-associated ophthalmopathy (GO), and existing lysosomal targeted chimera (Lytac) technology is not designed for TSHR, has complex synthesis, and may induce immunogenicity.
We designed a lysosomal targeting chimera (TSHR-Lytac) that targets the thyroid-stimulating hormone receptor. By constructing a TSHR nanobody with an IGF-2R binding peptide linker, we can achieve selective lysosomal degradation of TSHR and reduce TSHR expression on the cell surface.
This study achieved selective degradation of TSHR, reduced pathological effects, improved the pathological state of hyperthyroidism and GO, provided a new targeted degradation strategy, and reduced synthetic complexity and potential immunogenicity.
Smart Images
Figure CN122404567A_ABST